Publications by authors named "Marco F Eigenmann"
Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study.
Xenofon Baraliakos Mikkel Østergaard Denis Poddubnyy Désirée van der Heijde Atul Deodhar Marco F Eigenmann
Arthritis Rheumatol
August 2024
Article Synopsis
- The phase IIIb SURPASS study aimed to compare spinal radiographic progression in patients with radiographic axial spondyloarthritis who were treated with secukinumab (an interleukin-17A inhibitor) versus adalimumab biosimilar (a tumor necrosis factor inhibitor).
- The study involved 859 biologic-naive patients at high risk for progression, assessing outcomes like the proportion with no progression after 104 weeks and the safety of the treatments.
- Results showed no significant difference in radiographic progression between secukinumab and adalimumab biosimilar, with overall low progression rates observed in all treatment groups and no unexpected safety issues reported.